Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, Bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, Bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
Who We Are. Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's. The company’s lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibit...
